Literature DB >> 31362997

Natural Killer Cell Recruitment and Activation Are Regulated by CD47 Expression in the Tumor Microenvironment.

Pulak Ranjan Nath1, Dipasmita Pal-Nath2, Ajeet Mandal3, Margaret C Cam4, Anthony L Schwartz2, David D Roberts1.   

Abstract

Elevated CD47 expression in some cancers is associated with decreased survival and limited clearance by phagocytes expressing the CD47 counterreceptor SIRPα. In contrast, elevated CD47 mRNA expression in human melanomas was associated with improved survival. Gene-expression data were analyzed to determine a potential mechanism for this apparent protective function and suggested that high CD47 expression increases recruitment of natural killer (NK) cells into the tumor microenvironment. The CD47 ligand thrombospondin-1 inhibited NK cell proliferation and CD69 expression in vitro Cd47 -/- NK cells correspondingly displayed augmented effector phenotypes, indicating an inhibitory function of CD47 on NK cells. Treating human NK cells with a CD47 antibody that blocks thrombospondin-1 binding abrogated its inhibitory effect on NK cell proliferation. Similarly, treating wild-type mice with a CD47 antibody that blocks thrombospondin-1 binding delayed B16 melanoma growth, associating with increased NK cell recruitment and increased granzyme B and interferon-γ levels in intratumoral NK but not CD8+ T cells. However, B16 melanomas grew faster in Cd47 -/- than in wild-type mice. Melanoma-bearing Cd47 -/- mice exhibited decreased splenic NK cell numbers, with impaired effector protein expression and elevated exhaustion markers. Proapoptotic gene expression in Cd47-/- NK cells was associated with stress-mediated increases in mitochondrial proton leak, reactive oxygen species, and apoptosis. Global gene-expression profiling in NK cells from tumor-bearing mice identified CD47-dependent transcriptional responses that regulate systemic NK activation and exhaustion. Therefore, CD47 positively and negatively regulates NK cell function, and therapeutic antibodies that block inhibitory CD47 signaling can enhance NK immune surveillance of melanomas. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31362997      PMCID: PMC6726576          DOI: 10.1158/2326-6066.CIR-18-0367

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  69 in total

Review 1.  Mitochondrial control of cell death.

Authors:  G Kroemer; J C Reed
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

Review 2.  Genetic and functional relationships between MHC and NK receptor genes.

Authors:  J Trowsdale
Journal:  Immunity       Date:  2001-09       Impact factor: 31.745

3.  Role of CD47 as a marker of self on red blood cells.

Authors:  P A Oldenborg; A Zheleznyak; Y F Fang; C F Lagenaur; H D Gresham; F P Lindberg
Journal:  Science       Date:  2000-06-16       Impact factor: 47.728

4.  Thrombospondin-1 inhibits TCR-mediated T lymphocyte early activation.

Authors:  Z Li; L He; K Wilson; D Roberts
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

5.  Specific and nonspecific NK cell activation during virus infection.

Authors:  A O Dokun; S Kim; H R Smith; H S Kang; D T Chu; W M Yokoyama
Journal:  Nat Immunol       Date:  2001-10       Impact factor: 25.606

6.  "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype.

Authors:  R Kiessling; E Klein; H Wigzell
Journal:  Eur J Immunol       Date:  1975-02       Impact factor: 5.532

7.  Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells.

Authors:  R B Herberman; M E Nunn; H T Holden; D H Lavrin
Journal:  Int J Cancer       Date:  1975-08-15       Impact factor: 7.396

8.  Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells.

Authors:  B Seliger; U Wollscheid; F Momburg; T Blankenstein; C Huber
Journal:  Cancer Res       Date:  2001-02-01       Impact factor: 12.701

9.  Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity.

Authors:  Emilio Fiore; Carlo Fusco; Pedro Romero; Ivan Stamenkovic
Journal:  Oncogene       Date:  2002-08-08       Impact factor: 9.867

10.  Murine cytomegalovirus is regulated by a discrete subset of natural killer cells reactive with monoclonal antibody to Ly49H.

Authors:  K A Daniels; G Devora; W C Lai; C L O'Donnell; M Bennett; R M Welsh
Journal:  J Exp Med       Date:  2001-07-02       Impact factor: 14.307

View more
  31 in total

1.  The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides.

Authors:  Oleg Kruglov; Lisa D S Johnson; Angela Minic; Kimberly Jordan; Robert A Uger; Mark Wong; Eric L Sievers; Yaping Shou; Oleg E Akilov
Journal:  Cancer Immunol Immunother       Date:  2021-09-14       Impact factor: 6.968

2.  CD47 (Cluster of Differentiation 47).

Authors:  Sukhbir Kaur; Jeffrey S Isenberg; David D Roberts
Journal:  Atlas Genet Cytogenet Oncol Haematol       Date:  2021

Review 3.  Emerging role of tumor cell plasticity in modifying therapeutic response.

Authors:  Siyuan Qin; Jingwen Jiang; Yi Lu; Edouard C Nice; Canhua Huang; Jian Zhang; Weifeng He
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

4.  THBS1 (thrombospondin-1).

Authors:  Jeffrey S Isenberg; David D Roberts
Journal:  Atlas Genet Cytogenet Oncol Haematol       Date:  2020

5.  Preclinical and Clinical Development of Therapeutic Antibodies Targeting Functions of CD47 in the Tumor Microenvironment.

Authors:  Sukhbir Kaur; Kyle V Cicalese; Rajdeep Bannerjee; David D Roberts
Journal:  Antib Ther       Date:  2020-08-08

6.  Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation.

Authors:  Anthony L Schwartz; Pulak R Nath; Michael Allgauer; Elizabeth C Lessey-Morillon; John M Sipes; Lisa A Ridnour; Y Maurice Morillon Ii; Zhiya Yu; Nicholas P Restifo; David D Roberts
Journal:  Cancer Immunol Immunother       Date:  2019-10-18       Impact factor: 6.968

Review 7.  Functions of Thrombospondin-1 in the Tumor Microenvironment.

Authors:  Sukhbir Kaur; Steven M Bronson; Dipasmita Pal-Nath; Thomas W Miller; David R Soto-Pantoja; David D Roberts
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 6.208

Review 8.  Strategies for Genetically Engineering Hypoimmunogenic Universal Pluripotent Stem Cells.

Authors:  Wei Zhao; Anhua Lei; Lin Tian; Xudong Wang; Cristina Correia; Taylor Weiskittel; Hu Li; Alan Trounson; Qiuli Fu; Ke Yao; Jin Zhang
Journal:  iScience       Date:  2020-05-17

9.  Identification of Schlafen-11 as a Target of CD47 Signaling That Regulates Sensitivity to Ionizing Radiation and Topoisomerase Inhibitors.

Authors:  Sukhbir Kaur; Anthony L Schwartz; David G Jordan; David R Soto-Pantoja; Bethany Kuo; Abdel G Elkahloun; Lesley Mathews Griner; Craig J Thomas; Marc Ferrer; Anish Thomas; Sai-Wen Tang; Vinodh N Rajapakse; Yves Pommier; David D Roberts
Journal:  Front Oncol       Date:  2019-10-01       Impact factor: 6.244

Review 10.  The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies.

Authors:  Tobias Bald; Matthew F Krummel; Mark J Smyth; Kevin C Barry
Journal:  Nat Immunol       Date:  2020-07-20       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.